Correction: Li et al. The Therapeutic Potential of ADSC-Secreted LEFTY2 in Treating Alzheimer’s Disease. Int. J. Mol. Sci. 2025, 26, 3382
Wei-Wu Li, Hsueh-Hui Yang, Tzyy-Wen Chiou, Peng-Yeong Woon, Yue-Xuan Xu, Cynthia Tjandra, Ivan Wijaya, Horng-Jyh Harn, Shinn-Zong Lin
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCholinesterase and Neurodegenerative Diseases
Missing Funding
In the original publication [1], the funder Gwo Xi Stem Cell Applied Technology Co., Ltd. (grant number: IAC-RD-21-002) was not included. The corrected Funding appears below:
Funding: This research was supported by the National Science and Technology Council, R.O.C (grant number NSTC 113-2314-B-303-005) and Gwo Xi Stem Cell Applied Technology Co., Ltd. (grant number: IAC-RD-21-002).
Conflicts of Interest Correction
The authors would like to modify the Conflict of interest Section of the following published paper [1]. The changes are below.
Conflicts of Interest: The authors declare that this study received funding from Gwo Xi Stem Cell Applied Technology Co., Ltd. (grant number: IAC-RD-21-002). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
The reference list from the paper itself. Each links out to its DOI / PubMed record.